Literature DB >> 8151296

Cytotoxic T lymphocytes raised against Japanese encephalitis virus: effector cell phenotype, target specificity and in vitro virus clearance.

K Murali-Krishna1, V Ravi, R Manjunath.   

Abstract

Several H-2 defined cell lines were examined for their ability to support infection and replication of Japanese encephalitis virus (JEV) before their use in in vitro and in vivo stimulation protocols for generating cytotoxic T lymphocytes (CTLs) against JEV. Among 11 different cell lines tested, two H-2d macrophage tumour lines (P388D1, RAW 264.7), an H-2d hybridoma (Sp2/0), an H-2KkDd neuroblastoma (Neuro 2a), and H-2k fibroblast cell line (L929) were found to support JEV infection and replication. These cell lines were used to generate anti-JEV CTLs by using in vivo immunization followed by in vitro stimulation of BALB/c mice. We observed that not only syngeneic and allogeneic infected cells but also JEV-infected xenogeneic cells could prime BALB/c mice for the generation of JEV-specific CTLs upon subsequent in vitro stimulation of splenocytes with JEV-infected syngeneic cells. Although infected xenogeneic cells were used for immunization, the anti-JEV effectors that were generated lysed infected syngeneic targets but not JEV-infected xenogeneic or allogeneic target cells in a 5 h 51Cr release assay. These anti-JEV effectors recognized syngeneic target cells infected with West Nile virus to a lesser extent and were shown to be Lyt-2.2+ T cells. The results of unlabelled cold target competition studies suggested alterations in the cell surface expression of viral antigenic determinants recognized by these CTLs. We further demonstrate that the JEV-specific CTLs generated could virtually block the release of infectious virus particles from infected P388D1 and Neuro 2a cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151296     DOI: 10.1099/0022-1317-75-4-799

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes.

Authors:  T Liu; T J Chambers
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses.

Authors:  C H Pan; H W Chen; H W Huang; M H Tao
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.

Authors:  Kerrie Vaughan; Jason Greenbaum; Martin Blythe; Bjoern Peters; Alessandro Sette
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

4.  Japanese encephalitis virus infection of mouse cell lines: ability to prime mice for generation of virus specific cytotoxic T lymphocytes and differences in CTL recognisable viral determinants.

Authors:  K Murali-Krishna; V Ravi; R Manjunath
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome.

Authors:  A S De Groot; C Saint-Aubin; A Bosma; H Sbai; J Rayner; W Martin
Journal:  Emerg Infect Dis       Date:  2001 Jul-Aug       Impact factor: 6.883

6.  Qualitative differences in brain-infiltrating T cells are associated with a fatal outcome in mice infected with Japanese encephalitis virus.

Authors:  Kenji Shirai; Daisuke Hayasaka; Kazutaka Kitaura; Tomohiko Takasaki; Kouichi Morita; Ryuji Suzuki; Ichiro Kurane
Journal:  Arch Virol       Date:  2015-01-22       Impact factor: 2.574

7.  Human T cell responses to Japanese encephalitis virus in health and disease.

Authors:  Lance Turtle; Tanushka Bali; Gemma Buxton; Savita Chib; Sajesh Chan; Mohammed Soni; Mohammed Hussain; Heather Isenman; Prachi Fadnis; Manjunatha M Venkataswamy; Vishali Satishkumar; Penny Lewthwaite; Ayako Kurioka; Srinivasa Krishna; M Veera Shankar; Riyaz Ahmed; Ashia Begum; Vasanthapuram Ravi; Anita Desai; Sutee Yoksan; Stefan Fernandez; Christian B Willberg; Henrik N Kloverpris; Christopher Conlon; Paul Klenerman; Vijaya Satchidanandam; Tom Solomon
Journal:  J Exp Med       Date:  2016-05-30       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.